Table 2.

Hazard ratios for association between BMI group and CRPC outcomes

	Metastases				All-cause mortality				Prostate cancer-specific mortality
	N	HR	95% CI	P	N	HR	95% CI	P	N	HR	95% CI	P
Unadjusted
BMI (continuous)^	659/1140	1.01	0.99–1.02	0.360	809/1138	0.98	0.97–0.99	0.026	527/1138	1.00	0.97–1.02	0.798
BMI Category
Underweight	27/51	1.15	0.73–1.80	0.554	37/51	1.35	0.95–1.93	0.097	21/51	1.19	0.71–1.97	0.512
Normal	122/239	1.00	Ref	-	174/239	1.00	Ref	-	97/239	1.00	Ref	-
Overweight	273/464	1.19	0.96–1.48	0.107	339/464	0.90	0.75–1.08	0.454	226/464	1.20	0.95–1.53	0.129
Obese	264/438	1.27	1.03–1.58	0.028	298/438	0.81	0.67–0.97	0.025	204/438	1.18	0.92–1.50	0.185
Adjusted*
BMI (continuous)^	659/1140	0.99	0.98–1.01	0.225	809/1138	0.98	0.97–0.99	0.012	527/1138	1.00	0.98–1.01	0.737
BMI Category
Underweight	27/51	1.20	0.75–1.90	0.450	37/51	1.38	0.96–1.98	0.083	21/51	1.14	0.67–1.95	0.629
Normal	122/239	1.00	Ref	-	174/239	1.00	Ref	-	97/239	1.00	Ref	-
Overweight	273/464	1.17	0.93–1.46	0.178	339/464	0.90	0.74–1.08	0.248	226/464	1.17	0.92–1.50	0.203
Obese	264/438	1.06	0.84–1.33	0.647	298/438	0.79	0.65–0.96	0.016	204/438	1.11	0.86–1.43	0.436

^*Adjusted for VA center and clinical characteristics: age at CRPC, race, year of CRPC diagnosis, treatment center, primary prostate cancer treatment, biopsy grade group, PSA at CRPC, and Charlson comorbidity index

The interaction between BMI (continuous) and Charlson comorbidity index (0, 1, 2, ≥3) was p=0.849 for metastases, p=0.672 for all-cause mortality, and p=0.942 for prostate cancer-specific mortality.